



康方生物科技(開曼)有限公司
Akeso, Inc.

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

Stock Code 股份代號 : 9926

2025

ENVIRONMENTAL, SOCIAL
AND GOVERNANCE REPORT

環境、社會
及管治報告



CONTENTS

1	ABOUT THIS REPORT	2
2	STATEMENT OF THE BOARD	3
3	ESG MANAGEMENT	4
3.1	ESG MANAGEMENT STRUCTURE	4
3.2	COMMUNICATION WITH STAKEHOLDERS	5
3.3	MATERIALITY ANALYSIS	7
4	COMPLIANCE AND GOVERNANCE: LAYING A SOLID FOUNDATION	8
4.1	BUSINESS ETHICS	8
4.1.1	Anti-corruption	8
4.1.2	Whistleblower Protection	9
4.2	INTELLECTUAL PROPERTY PROTECTION	9
4.3	RISK MANAGEMENT	10
4.4	RESPONSIBLE MARKETING	13
5	R&D AND PRODUCTION: PURSUING HIGHER QUALITY	14
5.1	QUALITY MANAGEMENT	14
5.1.1	Drug Manufacturing	14
5.1.2	Product Research and Development	18
5.1.3	Industry Communication	20
5.2	PHARMACOVIGILANCE	22
5.3	SUPPLY CHAIN MANAGEMENT	24
5.3.1	Supplier Management System	24
5.3.2	Sustainable Procurement	26
5.3.3	Supply Chain Integrity Construction	26
6	PEOPLE-CENTRIC: STRENGTHENING CORE COHESION	27
6.1	PROTECTION OF EMPLOYEE RIGHTS	27
6.1.1	Labor Rights and Interests	27
6.1.2	Communication with Employees	32
6.1.3	Remuneration and Benefits	32
6.2	DEVELOPMENT AND TRAINING	33
6.3	OCCUPATIONAL HEALTH AND SAFETY	35
6.3.1	Work Safety	35
6.3.2	Occupational Health	36
6.3.3	Chemical Management	37
7	GREEN OPERATIONS: SHAPING A SUSTAINABLE FUTURE	38
7.1	ENVIRONMENTAL MANAGEMENT SYSTEM	38
7.2	EMISSION MANAGEMENT	39
7.2.1	Waste Gas Treatment	39
7.2.2	Wastewater Management	40
7.2.3	Waste Management	41
7.3	RESOURCE USAGE MANAGEMENT	42
7.3.1	Energy Management	42
7.3.2	Water Resource Management	44
7.3.3	Packaging Material Management	45
7.4	RESPONSE TO CLIMATE CHANGE	45
7.4.1	Governance	45
7.4.2	Strategy	46
7.4.3	Risk Management	51
7.4.4	Metrics and Targets	51
8	PUBLIC WELFARE: EMPOWERING THE SOCIETY	52
9	APPENDIX: CONTENT INDEX OF APPENDIX C2 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING CODE	53

1 ABOUT THIS REPORT

OVERVIEW

This report is the sixth environmental, social, and governance (ESG) report issued by Akeso, Inc. for the period covering January 1, 2025 to December 31, 2025.

BASIS OF PREPARATION

This report is prepared in compliance with the Appendix C2 *Environmental, Social and Governance Reporting Code* to the Listing Rules and Guidance on the Stock Exchange of Hong Kong Ltd. The contents of this report are determined according to a set of systematic procedures, which include identifying and ranking key stakeholders and identifying and prioritizing material ESG issues, setting the scope and boundary of the ESG report, collecting relevant information and data, preparing reports based on such information, and reviewing the data contained herein.

This report is prepared in line with the reporting principles of materiality, quantification, balance and consistency. In this report, the Company illustrates how to identify and engage with our stakeholders, and determines the materiality matrix and key issues. On this basis, the Company has made quantitative disclosures on the key performance metrics and ensured that the report on its ESG performance is comprehensive and fair.

REPORTING SCOPE

The disclosure scope in this report is consistent with the 2025 annual report of Akeso, Inc., including the Company and its subsidiaries. A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company.

EXPLANATION FOR ABBREVIATIONS

For better presentation and understanding, each of “Akeso, Inc.”, “the Company” and “we” or “us” refers to “Akeso, Inc.” in this report.

SOURCE OF DATA AND RELIABILITY ASSURANCE

The data and other information contained in this report are mainly extracted from the relevant documents, reports and statistical results of Akeso, Inc. Akeso, Inc. undertakes that this report contains no false information or misleading statements, and is responsible for the truthfulness, accuracy and completeness of its contents.

CONFIRMATION AND APPROVAL

Upon the confirmation of the management, this report has been approved by the Board on March 26, 2026.

2 STATEMENT OF THE BOARD

Akeso, Inc. conducts its disclosure activities strictly in accordance with the requirements set forth in Appendix C2 *Environmental, Social and Governance Reporting Code* of the Stock Exchange of Hong Kong Ltd., consistently orienting itself toward sustainable development as a core strategic direction. The Company continuously enhances its environmental, social and governance (ESG) management system and advances relevant practices toward higher standards.

At the corporate governance level, the Board of Directors serves as the highest decision-making body for ESG matters, assuming full responsibility for planning, supervision, and governance to ensure the integration of all ESG initiatives with business development. We remain committed to creating sustainable value for the enterprise by addressing multiple dimensions — including environmental protection, employee well-being, and product quality assurance — while pursuing operational performance, and proactively fulfilling our social responsibilities.

To effectively embed ESG principles into strategy and daily operations, the Board regularly reviews the Company's operating conditions and industry trends, and maintains ongoing communication with internal and external stakeholders to systematically identify potential risks and opportunities. Based on the assessment of the materiality of key issues, we have clearly identified the annual ESG management priorities and established, as well as optimized, goals and implementation pathways accordingly. The relevant progress is continuously monitored by management, with improvement recommendations proposed for identified weaknesses and risk mitigation measures implemented. In addition, the Board meeting is held at least twice a year to review ESG-related matters in a focused manner, including receiving reports from the dedicated working group and reviewing the annual *Environmental, Social, and Governance Report*, thereby ensuring transparency in governance and effective implementation.

3 ESG MANAGEMENT

Akeso, Inc. continues to enhance its ESG governance framework led by the Board, systematically integrating decision-making, execution, and evaluation processes to ensure the robust implementation of its sustainability strategy. The Company places significant emphasis on stakeholder engagement, identifying key management priorities through materiality assessment to continuously enhance its ESG performance and long-term value.

3.1 ESG MANAGEMENT STRUCTURE

Akeso, Inc. has established an ESG governance framework extending from the Board of Directors to operational frontlines, grounded in business advancement and regulatory compliance. This structure enables full-cycle closed-loop management encompassing strategic decision-making, implementation, and performance evaluation, thereby providing robust governance support for the orderly progression toward ESG goals.

The Company's Board of Directors holds the ultimate decision-making responsibility for ESG matters, overseeing the development of sustainability strategies, action plans, and implementation standards. It regularly reviews ESG performance and progress, coordinates the systematic operation of the Company's ESG initiatives, and is committed to building a scientific, efficient, and sustainable ESG management system.

Under the leadership of the Board of Directors, the Company has established an Environmental, Social, and Governance (ESG) Working Group (the "ESG Working Group"), which collaborates with key departments, including the Administrative and Facilities Department, the Environment, Health and Safety (EHS) Department, the Human Resources Department, the Production Department, the Logistics and Procurement Department and the Quality Control Department to facilitate the implementation of ESG tasks. The ESG Working Group is responsible for developing the annual work plan, aligning with the current business conditions and stakeholder expectations, to identify key priorities and critical performance indicators. It monitors ongoing process and conducts outcome evaluation, and submits progress reports to the Board on a timely basis to ensure that sustainability requirements are effectively integrated into all aspects of daily operations.

3.2 COMMUNICATION WITH STAKEHOLDERS

Akeso, Inc. maintains a fundamental stance of achieving harmonious and win-win situation with its stakeholders. Through the establishment of diverse communication platforms, the enhancement of multi-channel engagement mechanisms, and the implementation of regular awareness initiatives, the Company continuously gathers and thoughtfully addresses the expectations and requirements of all parties involved. Building on this feedback, we continue to optimize the design of the ESG strategy and steadily advance the implementation of various sustainable development initiatives.

In 2025, we further strengthened efforts in food and drug safety, operational and production safety, green and low-carbon development, and ecological conservation, and continued to enhance the system of public welfare philanthropy and volunteer services. Meanwhile, we have strengthened end-to-end control in key areas such as New Drug Applications (NDA), license out, overseas research and development, intellectual property protection, advertising compliance, pharmaceutical e-commerce platforms, drug import and export compliance, and supply chain anti-corruption. These efforts are designed to effectively address stakeholders' concerns and advance the Company's ESG governance in a sound and pragmatic manner.

Table 1: List of Stakeholder Engagement of Akeso, Inc.

Stakeholders	Concerns	Communication and engagement channels
Shareholders	Compliance operation	Implementation of relevant policies
	Corporate governance enhancement	Strengthening of anti-corruption measures
	Transparent information disclosure	Efficient operational system
	International strategic cooperation	Enhancement of corporate governance
		Convening of shareholders' general meetings
		Improvement of communication with shareholders
		Regular information disclosure
Customers		Optimization of the cooperation platform
	Product quality control	Establishment of a comprehensive quality control system
	Innovative research and development platform	Enhancement of productivity
	Customer services	Improvement of research and development and innovation capacity
	Protection of intellectual property rights	Launch of customer satisfaction survey
	International strategic cooperation	Stringent protection measures for intellectual property rights
		Optimization of cooperation platform

3.2 COMMUNICATION WITH STAKEHOLDERS (Continued)

Stakeholders	Concerns	Communication and engagement channels
Employees	Caring for employees	Fostering of corporate culture
	Occupational health and safety	Introduction of employee communication mechanism
	Employee ability training	Enhancement of employee benefits
	Employment policy	Employee stock incentive plan
	Remuneration and benefits	Safeguarding of employees' health and safety
		Organization of training sessions for employees
		Fair recruitment
		Provision of reasonable remuneration packages
		Provision of reasonable promotion path
Government	Operational compliance	Implementation of relevant policies
	Transparent information disclosure	Enhancement of corporate governance
	Environmental protection	Strengthening of anti-corruption measures
	Emission management	Regular information disclosure
	Energy saving	Compliance with the environmental protection laws and regulations
		Reduction of pollutant emission
Suppliers	Sustainable supply chain management	Resources saving
	Compliance operation	Strengthening of procurement management
		Implementation of relevant policies
		Strengthening of anti-corruption measures
Community and the public	Promotion of local employment	
	Charitable activities for the community	School-enterprise cooperation
	Environmental protection	Organization of charitable activities
	Emission management	Compliance with the environmental protection laws and regulations
	Energy saving	Reduction of pollutant emission
	Use of resources	Enhancement of material and resource usage efficiency

3.3 MATERIALITY ANALYSIS

We have identified and assessed the 2025 material ESG issues of Akeso, Inc. by reviewing the 2024 material ESG issues and 2025 business development of the Company in conjunction with communications with the external and internal stakeholders.

Based on the materiality assessment result of the ESG issues of the Company from various stakeholders, we identified 21 ESG issues that have material impacts on Akeso, Inc., including 9 highly important issues, 10 moderately important issues, and 2 general issues.



Highly important issues	Moderately important issues		General Issues
1. Safety of clinical trial 2. Product quality and safety 3. Data security and privacy protection 4. Product R&D and innovation 5. Business ethics 6. Protection of intellectual property rights 7. Employee well-being 8. Employee development and training 9. R&D ethics	10. Occupational health and safety 11. Corporate governance 12. Sustainable supply chain management 13. Emission management 14. Employee rights	15. Access to healthcare 16. Industry cooperation and development 17. Resource management 18. Water usage 19. Energy usage	20. Community engagement 21. Response to climate change

4 COMPLIANCE AND GOVERNANCE: LAYING A SOLID FOUNDATION

Akeso, Inc. upholds the highest standards of business ethics, having established systematic mechanisms for anti-corruption and intellectual property protection. The Company ensures compliant operations through rigorous internal control and risk management systems, while adhering to principles of responsible market promotion. The Company continues to enhance its whistleblower protection and risk response measures, aiming to foster a sustainable development ecosystem characterized by integrity, transparency, and resilience.

4.1 BUSINESS ETHICS

Akeso, Inc. has established a comprehensive integrity and compliance system for all employees and a stringent whistleblower protection mechanism, resolutely preventing and combating fraudulent activities, thereby continuously reinforcing a business culture rooted in lawful operation and integrity.

4.1.1 Anti-corruption

Akeso, Inc. strictly abides by the *Company Law of the People's Republic of China* (《中華人民共和國公司法》), the *Anti-Unfair Competition Law of the People's Republic of China* (《中華人民共和國反不正當競爭法》), the *Bidding Law of the People's Republic of China* (《中華人民共和國招標投標法》), the *Anti-Money Laundering Law of the People's Republic of China* (《中華人民共和國反洗錢法》) and other relevant laws and regulations. We have formulated internal systems such as the *Anti-Fraud Management Measures* (《反舞弊管理辦法》) and the *Anti-Unfair Competition Management Measures* (《反不正當競爭管理辦法》) to rigorously prohibit and prevent illegal and non-compliant activities, including bribery, extortion, fraud, and money laundering.

We have established a comprehensive integrity and compliance system covering all personnel, requiring all new employees to sign the *Anti-commercial Bribery Undertaking Letter* (《反商業賄賂承諾書》) and complete training on business ethics and compliance upon onboarding, strictly adhering to the business ethics and behavioral standards outlined in the *Employee Handbook* (《員工手冊》). Employees in key positions are additionally required to sign the *Integrity and Self-discipline Undertaking Letter* (《廉潔自律承諾書》) and participate in specialized training on professional ethics and compliance. In addition, the Company conducts regular anti-corruption and compliance training for board members and all employees, continuously reinforcing an internal culture of operating in accordance with laws and regulations.

In external collaborations and supply chain management, we require all clients, suppliers, service providers, and contractors to sign the *Anti-commercial Bribery Undertaking Statement* (《反商業賄賂承諾函》), whereby they commit to maintaining integrity and self-discipline in business dealings. The Company strictly enforces this policy, and in principle, no business collaboration is conducted with external parties that have not signed the agreement as required, thereby establishing a clean, transparent, and sustainable external business ecosystem.

Table 2: Anti-corruption and Compliance Training Sessions for Akeso, Inc. Employees in 2025

Employee types	Number of trainees	Training rate (%)
Directors	8	66.7
Employees	3,752	99.8

4.1 BUSINESS ETHICS (Continued)

4.1.2 Whistleblower Protection

Akeso, Inc. has established a whistleblowing mechanism for employees and business partners to strengthen corporate integrity governance, enabling the submission of reports regarding various instances of fraud and non-compliance in either named or anonymous form. The President's Office serves as the dedicated body responsible for anti-fraud initiatives, centrally receiving and organizing reports of misconduct. Depending on the nature and severity of the reported matters, the President's Office promptly reports to company management or the Board of Directors and leads the organization of compliance investigations. An employee found to have engaged in fraudulent activities will be subject to disciplinary action in strict accordance with the *Reward and Punishment System* (《獎懲制度》). If criminal conduct is involved, the case will be referred to judicial authorities for legal handling. Throughout the entire process of receiving and investigating the report, we consistently prioritize the protection of the whistleblower's privacy, and the disclosure of any information that could identify the individual's identity has been strictly prohibited. If the investigators or their close relatives have a vested interest in the reported matter, recusal must be implemented to ensure the independence and impartiality of the investigation process.

In 2025, the Company did not identify any corruption-related lawsuits, or legal disputes settled or accepted.

4.2 INTELLECTUAL PROPERTY PROTECTION

Akeso, Inc. strictly complies with laws and regulations such as the *Patent Law of the People's Republic of China* (《中華人民共和國專利法》), the *Trademark Law of the People's Republic of China* (《中華人民共和國商標法》), and establishes a systematic intellectual property management framework in reference to the national standards GB/T 29490-2013 *Administration of Intellectual Property Rights of Enterprises* (《企業知識產權管理規範》). We place significant emphasis on the creation and protection of intellectual property. All employees are required to sign the *Confidentiality Agreement* (《保密協議》) and the *Confidentiality and Non-competition Agreement* (《保密與競業限制協議》) upon joining, to clearly define their respective responsibilities and obligations in safeguarding intellectual property.

The Company has established an independent Intellectual Property Department responsible for the periodic review and updating of management system documentation, as well as the ongoing monitoring of domestic and international patent developments and industry intellectual property landscapes. Additionally, the legal and R&D teams collaborate to conduct a systematic assessment of the Company's intellectual property management status, implement comprehensive IP risk management across all stages, and effectively prevent potential infringement risks. Furthermore, we have extended intellectual property protection requirements to supply chain management, explicitly stipulating in our agreements with suppliers that the products or services provided must not infringe upon any third-party intellectual property rights or other legitimate interests, thereby establishing an integrated intellectual property protection framework encompassing both internal and external parties.

Table 3: Intellectual Property Process Status of Akeso, Inc. in 2025

Total accumulated number of patent applications	Total accumulated number of trademark applications
1,085 patents	534 trademarks
Total accumulated number of issued patents	Total accumulated number of issued trademarks
218 patents	434 trademarks

4.2 INTELLECTUAL PROPERTY PROTECTION (Continued)

Akeso, Inc. continues to strengthen its pharmaceutical anti-counterfeiting and traceability management system, ensuring drug quality and patient medication safety. In the production stage, we establish a multi-level traceability and anti-counterfeiting mechanism, with data uploaded in real time to the National Drug Traceability Platform, ensuring that each product possesses a unique, traceable digital identity. Consumers can scan the code to access drug information, achieving end-to-end traceability and authenticity verification. To further enhance anti-counterfeiting capabilities, we use special anti-counterfeiting sealing labels to the opening of the drug packaging, improving its tamper-evident and anti-replication properties. During distribution and market supervision, the Company utilizes ongoing market research and a digital risk monitoring system to dynamically track drug circulation, actively collect clinical feedback and regulatory information, promptly respond to and rigorously investigate suspected counterfeit or substandard products, and fully safeguard market order and public health interests.

4.3 RISK MANAGEMENT

Akeso, Inc. has established a systematic risk management and internal control framework under the leadership of the Board. The Board has established an Audit Committee composed of three independent non-executive directors, which is responsible for providing independent oversight and opinion regarding the effectiveness of internal controls and risk management. In addition, the Company establishes a dedicated position responsible for the identification, assessment, and ongoing monitoring of risks, with related activities reported directly to the Board, ensuring that risk control mechanisms are integrated throughout all aspects of enterprise operations. The risk management framework is effectively operated through the routine collection of risk information, assessment of key risks, and implementation of risk mitigation measures.

To continuously strengthen risk prevention and control capabilities, we engage an external professional institution annually to conduct specialized audits, ensuring the security of information systems and compliant operations, as well as assessing the reasonableness and effectiveness of implementation of internal controls, thereby further enhancing corporate governance and risk mitigation. We place significant emphasis on the coordination of internal and external risk control mechanisms. For identified audit findings and recommendations, we assess based on their potential impact and likelihood of occurrence, and establish corresponding risk management improvement plans. In addition, a comprehensive and dynamic risk management framework has been established through the integration of ongoing internal monitoring and external professional auditing, enabling full coverage and continuous oversight across multiple dimensions including operations, finance, compliance, and information technology, thereby enhancing the enterprise's operational resilience and long-term sustainability.

4.3 RISK MANAGEMENT (Continued)

Table 4: Risks and Response Measures for Akeso, Inc. in 2025

Risk category	Risk description	Response measures
Foreign exchange risk	Due to overseas financing, international cooperation, foreign sales, and procurement activities, significant foreign currency assets and liabilities are held, whereby exchange rate fluctuations may result in foreign exchange losses, adversely affect financial performance, influence investors' assessments, and increase the cost of overseas operations or erode the value of revenue.	• Hedge a portion of cash flows using derivative instruments such as forward foreign exchange contracts • Through natural hedging to match foreign currency inflows and outflows, reduce the net risk exposure. • Regularly monitor exchange rate trends and exposure, and report to management and the Audit Committee.
International political and trade environment risks	Changes in international relations, geopolitical dynamics, or trade policies may constrain technological collaboration, impede the import of critical materials, and affect product exports, thereby threatening supply chain security, research and development timelines, and expansion into overseas markets.	• Enhance research on domestic substitution of key raw materials and equipment to reduce reliance on a single region. • Promote diversified deployment among partners and markets to mitigate concentration risks associated with geopolitical factors. • Continuously monitor international developments, conduct scenario forecasting, and establish contingency plans.

4.3 RISK MANAGEMENT (Continued)

Risk category	Risk description	Response measures
Risk associated with new drug development	The drug development cycle is lengthy, capital-intensive, and characterized by high technical risks. Clinical trials may fail due to issues related to efficacy, safety, or pharmaceutical quality, resulting in financial losses, setbacks in pipeline development, and adverse impacts on the Company's reputation and market valuation.	• Enhance target validation and translational research to increase the probability of success for candidate drugs • Optimize multi-stage, multi-platform, and multi-domain R&D pipelines to diversify project risk • Conduct rigorous internal and external review at critical junctures, with project continuation or termination determined based on data-driven decisions.
Production and quality risks	A deviation, contamination, equipment failure, or operational error in the production process may result in batch rejection, supply disruption, and potentially lead to quality and safety incidents, regulatory penalties, product recalls, and legal proceedings, thereby damaging brand reputation.	• Strictly enforce compliance with international and Chinese GMP regulations to ensure full compliance throughout the production process. • Establish a comprehensive quality control system spanning from supply chain to product release, and conduct regular audits for continuous improvement. • Implement preventive maintenance of critical equipment and ongoing process validation, establish emergency response plans, and conduct personnel training and drill exercises.

4.4 RESPONSIBLE MARKETING

Akeso, Inc. adheres to the highest standards of scientific integrity and business ethics, consistently upholding professional, compliant, and transparent principles in all medical communications and marketing activities. We regard responsible marketing not only as fundamental to ensuring patient safety and maintaining the trust of healthcare professionals, but also as a key driver of the Company's sustainable development. To this end, the Company has established an internal governance to ensure that all external communications and promotional activities are grounded in rigorous scientific evidence and strictly comply with applicable laws, regulations, and policies worldwide and at operational locations.

The Company has developed and implemented a comprehensive ethics and compliance training program for our marketing and sales teams. The training program comprehensively covers the Company's Code of Conduct, promotional activity compliance policies, anti-corruption laws and regulations, as well as specific guidelines for communication and interaction with healthcare professionals. Through ongoing education and reinforcement, we ensure that all relevant employees fully understand and consistently apply these compliance requirements, embodying our core "patient-first" principle in their daily work.

5 R&D AND PRODUCTION: PURSUING HIGHER QUALITY

Akeso, Inc. consistently positions quality management at the strategic core, establishing a scientific quality management system that spans research and development, manufacturing, and the entire product lifecycle, ensuring compliance with the highest international standards at every stage. The Company upholds the principle of “patient safety first” by establishing an active and intelligent drug safety monitoring and risk management mechanism, thereby ensuring continuous protection of product safety. Meanwhile, the Company enhances supply chain resilience and security, establishing close, stable, and mutually beneficial relationships with supply chain partners to foster a sustainable industrial ecosystem.

5.1 QUALITY MANAGEMENT

Akeso, Inc. consistently regards the high-quality production of pharmaceuticals as the cornerstone of its enterprise development, continuously advancing its product pipeline strategy that integrates in-house R&D with international collaboration. The Company actively participates in high-level industry exchanges and collaborations both domestically and internationally, aiming to promote the translation and application of cutting-edge technologies to provide global patients with more accessible and effective treatment options.

5.1.1 Drug Manufacturing

Akeso, Inc. continues to establish and enhance a comprehensive quality compliance system aligned with international standards while addressing local regulatory requirements. The Company strictly adheres to national and international laws, regulations, and guidelines, including but not limited to the *Drug Administration Law of the People's Republic of China* (《中華人民共和國藥品管理法》), the *Administrative Measures for Drug Registration* (《藥品註冊管理辦法》), the *Title 21 of the United States Code of Federal Regulations* (《美國聯邦法規》) (21 CFR), the *Administrative Measures for the Supervision of Pharmaceutical Manufacturing* (《藥品生產監督管理辦法》), the *Good Manufacturing Practice of Medical Products* (《藥品生產質量管理規範》) (GMP), the *Notice of Enhancing the Supervision of Drug Marketing Authorization Holders that Outsource Manufacture* (the 2023 No. 132) (《加強藥品上市許可持有人委託生產監督管理工作的公告》(2023年第132號)), the *Announcement on Strengthening the Supervision and Administration of Entrusted Production* (No. 134, 2025) (《加強藥品受託生產監督管理工作的公告》(2025年第134號)), and the *Chinese Pharmacopoeia* (2025 Edition). Furthermore, the Company actively refers to internationally recognized standards, such as those issued by the Therapeutic Goods Administration (TGA) of Australia and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The Company employs a dynamic and continuously improving quality management system that covers the entire value chain from R&D, clinical trials, manufacturing, to post-marketing activities, reinforcing the primary responsibility of the marketing authorization holder for pharmaceutical quality. The system enables systematic optimization of the quality authorized person management, and incorporates advanced process guidelines such as ICH Q13 on continuous manufacturing, driving the upgrading of the production system through technological innovation. On this basis, the Company has further strengthened its capability in quality control throughout the entire lifecycle of pharmaceutical products, continuously ensuring product safety, efficacy, and compliance.

5.1 QUALITY MANAGEMENT (Continued)

5.1.1 Drug Manufacturing (Continued)

Akeso, Inc. treats the dynamic refinement of its quality management system and full-process compliance as central to enterprise operations. Through systematically designed, standardized procedures and continuous improvement, the Company ensures that all pharmaceutical production processes conform to stringent internal and external standards. The Company has established and implemented a periodic quality review mechanism, under which the quality of production and operations is systematically monitored and evaluated in accordance with the *Quality Control Evaluation Management* (《質量管理評審管理程序》), continuously ensuring that the quality management system meets regulatory requirements, customer expectations, and the Company's internal quality objectives. The Company strictly adheres to a series of standardized documents, including the *GMP Records Management Procedures* (《GMP記錄管理程序》), the *Self-inspection Management Procedures* (《自檢管理程序》), the *Document Management Procedures* (《文件管理程序》), the *Change Control Management Procedures*, the *Production Authorization Management Procedures* (《變更控制管理程序》), and the *Deviation Management Procedures* (《偏差管理程序》), comprehensively covering key quality execution areas such as production authorization, document management, change control, deviation handling, and self-inspection. Through systematic and structured management practices, the Company has achieved substantial progress in standardizing control over pharmaceutical production and ensuring quality throughout the entire supply chain, laying a solid foundation for the consistent delivery of safe, stable, and high-quality pharmaceutical products.

Product Quality Management

The Company strictly adheres to regulatory requirements, including the *Good Manufacturing Practice of Medical Products* (《藥品生產質量管理規範》) and the *Title 21 of the United States Code of Federal Regulations* (《美國聯邦法規》) (21 CFR), and continuously enhances its quality management processes encompassing documentation, training, validation, supplier audits, risk management, and self-inspection. We design and implement standardized procedures to ensure that all production and quality activities are conducted in a consistent, traceable, and rule-based manner. We perform systematic confirmation and validation for critical facilities, equipment, and manufacturing processes to ensure they remain in a controlled and effective operational state at all times. The Company has established a Quality Risk Management Team, which employs professional tools such as Failure Mode and Effect Analysis (FMEA) and Hazard Analysis Critical Control Point (HACCP) to systematically identify quality risks throughout the product lifecycle, conduct scientific assessments, and develop control measures. Meanwhile, through regular self-inspections of the quality system, we identify and address deficiencies in system operation promptly, and establish corrective and preventive actions, ensuring that the quality management system remains consistently compliant with regulatory requirements and industry standards.

In addition, all employees of the Company are required to pass pre-employment and ongoing training assessments prior to assuming their respective positions, ensuring clarity regarding their job responsibilities and possession of the knowledge and skills necessary for effective performance. In material management, key suppliers are subject to a tiered assessment and audit process. A qualified supplier list and quality records are established and maintained to ensure compliance and stability of materials from the source.

5.1 QUALITY MANAGEMENT (Continued)

5.1.1 Drug Manufacturing (Continued)

Product Quality Management (Continued)

In 2025, the Company, leveraging digital transformation as an opportunity, continued to advance the synergistic optimization and functional reengineering of the Quality Management System (QMS) and Laboratory Information Management System (LIMS), achieving full digitalization and transformation of quality control, laboratory operations, and document workflows. By embedding management controls into system configurations, we have not only established real-time quality data monitoring capabilities across the entire process flow but also advanced the automated execution of inspection procedures and full-cycle documentation traceability, significantly enhancing the precision of quality control and overall operational efficiency.

Product Recall Management

To strengthen the primary responsibility for pharmaceutical safety, the Company has established a system of procedures according to the *Measures for Supervision and Administration of Drug Recall* (《藥品召回管理辦法》) and other relevant regulations issued by pharmaceutical regulators, including the *Product Recall Management Procedures* (《產品召回管理程序》), the *Reject Management Procedures* (《不合格品管理程序》), the *Return Handling and Management Procedures* (《退貨處理管理程序》), and the *Pharmaceutical Safety Incident Response Management Procedures* (《藥品安全事件處置管理程序》). The Company continuously improves its emergency response mechanisms, enhancing its capability to manage pharmaceutical safety incidents and strengthening risk management throughout the product lifecycle. For products involved in quality complaints, adverse effects, and similar circumstances, the Company strictly implements risk classification assessments and lawfully takes corresponding recall actions. All products returned due to quality issues are recorded in accordance with regulations and subject to supervised destruction. We have achieved closed-loop risk management to ensure that responsibilities for pharmaceutical safety control are fully implemented. During the Reporting Period, the Company did not experience any sold or shipped product recall due to safety and health concerns, and there were no product-related complaints related to safety and health concerns regarding the products.

In August 2025, the Company carried out simulated product recall emergency drills conducted a product recall simulation exercise, which effectively evaluated the operational feasibility of the recall policies and procedures, strengthened the coordinated response capability of relevant departments in the event of a sudden contingency quality incident, and ensured that the Company could promptly and orderly execute the recall processes when necessary.

5.1 QUALITY MANAGEMENT (Continued)

5.1.1 Drug Manufacturing (Continued)

Product Quality Training

The Company places great emphasis on the development of quality talent and the continuous improvement of its systems, organizing systematic training and qualification assessments annually for employees at all levels, covering fundamental topics such as pharmaceutical laws and regulations, GMP guidelines, and microbial control. Meanwhile, we actively arrange for employees to participate in external specialized training sessions on policies related to drug marketing authorization holder (MAH) delegated manufacturing, interpretation of measures for the administration of quality authorized persons of Guangdong Province, as well as cutting-edge technologies such as process scale-up and bioreactor applications, thereby comprehensively enhancing employees' awareness of quality compliance and professional management capabilities.

To further consolidate the effectiveness of the quality management system, we continue to enhance the quality management review mechanism by conducting quarterly quality evaluation meetings to periodically evaluate the quality management implementation of all departments, thereby providing institutional safeguards and organizational support for the efficient achievement of the Company's quality objectives.

Management of Counterfeit and Substandard Products

Akeso, Inc. consistently treats drug counterfeiting prevention and end-to-end traceability as critical components of its quality management framework, establishing a multi-tiered traceability and anti-counterfeiting system. In the production process, the Company implements dual-level labeling management from the smallest packaging unit to external shipping packaging. A Level 1 electronic traceability code is printed on the individual box, while a Level 2 supervision code is printed on the outer packaging carton. These multi-level codes are linked and uploaded to the National Drug Traceability Platform, ensuring each pharmaceutical unit possesses a unique, traceable digital identity and enabling transparent, end-to-end management across the entire production and distribution chain. In addition, special anti-counterfeiting sealing labels are applied at the top opening and bottom of the pharmaceutical blister packs to further enhance the anti-counterfeiting effectiveness. In the stages of distribution and market supervision, we rely on dynamic market research and an online product flow monitoring system to continuously track the distribution pathways of pharmaceuticals and closely monitor clinical usage feedback, enabling rapid response to any abnormal distribution activities. Through proactive monitoring and collaborative oversight, the Company has effectively mitigated the risk of counterfeit and substandard pharmaceuticals circulating in the market, thereby ensuring patient medication safety and maintaining market order.

5.1 QUALITY MANAGEMENT (Continued)

5.1.2 Product Research and Development

Akeso, Inc. drives innovation in research and development, adhering strictly to the highest ethical standards and establishing a scientific, standardized, and responsible R&D management system. We maintain compliance throughout the entire lifecycle from drug discovery to clinical translation, ensuring that each research activity adheres to international and domestic ethical standards and regulatory requirements, with commitment to patient-centered innovation in drug development.

Research and Development Management

Akeso, Inc. strictly complies with relevant laws, regulations, and requirements, including the *Drug Administration Law of the People's Republic of China* (《中華人民共和國藥品管理法》), the *Good Manufacturing Practice for Drugs* (《藥品生產質量管理規範》), and the *Clinical Investigational Product (Trial)* (《臨床試驗用藥品(試行)》). In 2025, the Company introduced additional internal management policies, namely the *Internal Audit Management Guidelines for R&D Department* (《研發部門自檢管理指南》), the *Guidelines for Classification and Quality Control Management of R&D Materials* (《R&D物料分級與質量控制管理指南》), and the *Guidelines for Management of Updates to Non-clinical Study Data for Products* (《產品非臨床研究數據更新管理指南》), providing clear institutional basis for continuous improvement of the quality system, assurance of material quality, and timely data updates. Meanwhile, the Company has revised and improved more than ten management guidelines, including research and development documentation, change control, deviation management, corrective and preventive actions (CAPA), quality risk assessment, supplier management, on-site monitoring, data review, and product release. This comprehensive enhancement ensures full coverage across critical stages — from material control and production monitoring to data integrity and outsourced services — thereby establishing clear procedures and documented evidence for all research and development quality management activities.

In addition, the Company conducts regular self-inspections and quality reviews based on the aforementioned institutional framework, strengthens change control and incident management, implements rigorous material classification and supplier management, and enhances monitoring at production sites, data review, and product release procedures, thereby comprehensively improving the controllability and compliance of the R&D process.

Akeso, Inc. adheres to a clear research and development strategy, guided by clinical value, with the “IO 2.0 + ADC 2.0” dual engine driving force at its core, focusing on the iterative advancement of oncology immunotherapy, while actively expanding into the fields of autoimmune and metabolic diseases. The Company has comprehensively positioned itself around its core dual-targeted antibodies, Cadonilimab and Ivonescimab, with a focus on major indications and combination therapies. Resources are concentrated on advancing the next-generation ADC 2.0 technology platform, while continuously developing next-generation technology platforms, including multispecific antibodies and mRNA vaccines. In 2025, the Company achieved significant milestones in its core products: the first-line cervical cancer indication for Cadonilimab was approved; Ivonescimab demonstrated superior efficacy again in a head-to-head study. The internationalization process accelerated, with Penpulimab monoclonal antibody receiving approval from the US FDA, and Ivonescimab's marketing application pending submission. Major progress was made in the autoimmune disease field, with Ebdarokimab approved for marketing and Manfidokimab entering the application stage. The Company's first bispecific ADC entered global clinical trials, and the mRNA tumor vaccine completed its first patient dosing. Five independently developed new drugs were successfully included in the National Reimbursement Drug List.

5.1 QUALITY MANAGEMENT (Continued)

5.1.2 Product Research and Development (Continued)

Adherence to Ethics

Akeso, Inc. upholds business ethics and research integrity, strictly adhering to applicable laws, regulations, and industry ethical standards in its research and development activities. This ensures that clinical studies and animal experiments are conducted in compliance with regulatory requirements, with full respect for and protection of the legitimate rights and interests of all parties involved.

The Company strictly adheres to ethical guidelines and regulatory requirements, including the *Declaration of Helsinki* (《赫爾辛基宣言》) and the *Measures for the Ethic Review of Life Sciences and Medical Science Research Involving Human* (《涉及人的生命科學和醫學研究倫理審查辦法》), and has established a robust ethical review mechanism. All clinical studies must be conducted only after participants have provided informed consent voluntarily, thereby ensuring their right to autonomous decision-making and the ability to withdraw at any time. Personal information and privacy of participants are protected in accordance with the highest standards, with measures implemented to prevent risks of data breaches.

At the same time, the Company strictly complies with regulations such as the *Regulations for the Administration of Affairs Concerning Experimental Animals* (《實驗動物管理條例》), the *Laboratory Animal — Guideline for Ethical Reviews of Animal Welfares* (《實驗動物福利倫理審查指南》), and the *Regulations for the Administration of Affairs Concerning Experimental Animals of Guangdong* (《廣東省實驗動物管理條例》), and fully implements the relevant requirements stipulated in the *Guiding Opinions for the Care of the Experimental Animals* (《關於善待實驗動物的指導性意見》), systematically ensuring animal welfare and experimental ethics from institutional and managerial perspectives. The Company has established an Experimental Animal Management Committee and an Ethics Committee, which have developed and continuously improved a comprehensive system of supporting regulations, including management bylaws, operating guidelines, emergency response plans, and ethics review standards, to ensure the necessity, compliance, and standardization of experiments.

In 2025, we further strengthened the ethical practice of animal experimentation based on the principle of “Reduction, Replacement and Refinement” (3R principles), optimized the ethics approval process, and enhanced oversight of experimental design and execution. In addition, we continuously enhance professional capacities and ethical awareness through regular training programs on operational standards and ethics for laboratory personnel, thereby minimizing the impact of experiments on animals to the greatest extent possible and fulfilling our solemn commitment to animal welfare ethics.

5.1 QUALITY MANAGEMENT (Continued)

5.1.3 Industry Communication

Akeso, Inc. regards open collaboration and industry engagement as critical pathways for driving innovation and development. By actively participating in domestic and international academic forums, industry dialogues, and strategic partnership initiatives, the Company continuously expands its industry perspective and integrates cutting-edge resources, with commitment to fostering a collaborative innovation ecosystem within the sector. In 2025, the Company participated in more than 20 national academic conferences in the oncology field, covering multiple tumor types including lung cancer, gastric cancer, and cervical cancer. Experts were invited to present the latest research data on the product, and in-depth discussions were held with clinical specialists regarding the product's value. In addition, the Company has engaged in multiple annual projects in close collaboration with the Chinese Anti-Cancer Association, covering areas such as discipline development, enhancement of clinical diagnostic and treatment capabilities, and training of mid-career and young physicians.

Case: Akeso, Inc. and TransThera Have Entered into a Strategic Collaboration to Advance the Development of a Combination Therapy Using Cadonilimab/Ivonescimab in Conjunction with Tinengotinib for the Treatment of Advanced Hepatocellular Carcinoma

In 2025, Akeso, Inc. entered into a strategic partnership with TransThera Sciences (Nanjing), Inc. The two parties are jointly advancing an open-label, multi-center Phase II clinical study evaluating the combination of Cadonilimab—a globally first-in-class PD-1/CTLA-4 dual-targeted antibody, and Ivonescimab, a novel PD-1/VEGF dual-targeted antibody, both developed independently by the Company, with Tinengotinib (TT-00420), an innovative multiple kinase small molecule inhibitor developed independently by TransThera, for the treatment of advanced hepatocellular carcinoma (HCC), aiming to provide more effective anti-tumor therapeutic options for patients.

Case: The China Solution Driving the Global Transformation of Oncology Treatment — Akeso, Inc. Unveils World-First Dual-Antibody at Guangzhou Medical Expo

In 2025, the Guangzhou Medical and Health Industry Expo (hereinafter referred to as “Guangzhou M-Expo”) was grandly launched. Akeso, Inc. showcased a portfolio of multiple independently developed, high-impact innovative pharmaceutical products, highlighting its breakthrough advancements in the treatment of diseases such as tumor immunology. The current M-Expo has facilitated a more precise understanding of the clinical value of innovative therapies developed by enterprises, enabling them to timely identify the latest clinical needs. This facilitates the acceleration of translating innovative pharmaceuticals from research and development into clinical application, thereby effectively enhancing their accessibility.

5.1 QUALITY MANAGEMENT (Continued)

5.1.3 Industry Communication (Continued)

Case: Akeso, Inc. Has Entered into A Strategic Partnership with the First Affiliated Hospital of Zhengzhou University to Jointly Initiate a New Chapter in Medical-Research Collaboration

On September 17, 2025, Akeso, Inc. actively advanced the “medical-research-industry collaboration” model and promoted the full-chain development of innovative pharmaceuticals, entering into a strategic partnership with the First Affiliated Hospital of Zhengzhou University. Both parties will take this signing ceremony as an opportunity to further expand the scope of cooperation and deepen its substantive content, with intensified efforts in areas such as clinical research on innovative drugs, joint training of scientific and research talents, and key research on the prevention and treatment of major diseases, thereby contributing more substantially to the establishment of a national medical center, the transformation into a research-oriented hospital, and the wellbeing of people in Henan Province.



Fig: Strategic Partnership Initiative

5.2 PHARMACOVIGILANCE

Akeso, Inc. consistently prioritizes patient safety and strictly adheres to domestic and international regulatory requirements pertaining to pharmaceutical safety, including the *Drug Administration Law of the People's Republic of China* (《中華人民共和國藥品管理法》), the *Measures for the Reporting and Monitoring of Adverse Drug Reactions* (《藥品不良反應報告和監測管理辦法》), the *Good Pharmacovigilance Practice* (《藥物警戒質量管理規範》) (GVP), and ICH guidelines. The Company has established a pharmacovigilance management system deeply integrated with its quality strategy framework and developed a series of pharmacovigilance operating procedures and policy documents covering activities such as collection, handling, and reporting of adverse drug reactions, signal detection, analysis evaluation, risk identification, and risk mitigation. These measures ensure that the pharmacovigilance system operates in strict compliance with applicable regulations and with high efficiency throughout the entire lifecycle of medicinal products, thereby effectively safeguarding the safety, rationality, and effectiveness of medicinal product use by the public. In 2025, the Company introduced and enhanced multiple internal management systems and standard operating procedures, including the *Procedure for Management of Direct Reporting System for Adverse Drug Reactions* (《藥品不良反應直接報告系統管理程序》), the *Process for Handling Complaint Events Originating from Hotline Channels* (《熱線來源投訴事件處理流程》), the *Procedure for Data Backup and Disaster Recovery Management within the PV System* (《PV系統數據備份及災難恢復管理程序》), and the *Post-Approval Safety Surveillance Enhancement Process* (《藥品上市後加強監測流程》). These measures further strengthened the systematic nature, response speed, and data reliability of the Company's pharmacovigilance system, thereby effectively fulfilling the enterprise's primary responsibility for safety.

Akeso, Inc. has established a drug safety management framework with clearly defined responsibilities, smooth operations, and timely responses, clarifying the core decision-making function of the Drug Safety Committee, and detailing its review procedures to ensure scientific decision-making and efficient response in the event of significant safety incidents. The Pharmacovigilance Department, as an independent functional unit, comprises specialized modules including Safety Operations, Safety Monitoring, Safety Science, Quality Standards, and Training. It is responsible for the comprehensive management of adverse reactions, signal detection, risk assessment, and compliance training. Through the enhancement of cross-functional collaboration mechanisms, overall operational efficiency has been further improved.

To ensure patient safety effectively, the Company has established a quality assessment system covering the entire pharmacovigilance process. This system defines multidimensional, quantifiable quality control indicators, including compliance with adverse drug reaction reporting, compliance with periodic safety update reports, and timeliness of signal detection and evaluation, which are assessed on a monthly, quarterly, and annual basis. Meanwhile, the Company conducts ongoing quality reviews and internal audits, directly utilizing the assessment results to optimize business processes and implementing a tiered, closed-loop management approach for identified issues, thereby establishing a mechanism for continuous improvement.

5.2 PHARMACOVIGILANCE (Continued)

Pharmacovigilance Assessment and Communication Mechanism

We continuously monitor risks associated with pharmaceutical products entering the market and supply chain, and maintain dynamic communication with stakeholders including patients, healthcare professionals, ethics committees, and regulatory authorities, including promptly reporting and disseminating the safety information regarding our products, and implement risk mitigation measures based on evidence-based data, fulfilling our responsibility for product safety throughout the entire lifecycle. To facilitate the reporting of adverse drug events by patients, hospitals, and other parties, we have established clear and accessible feedback channels, including a 400 service hotline, an official website platform, and a dedicated pharmacovigilance email. Upon receipt of adverse reaction information related to clinical trials or post-marketing pharmacovigilance, we strictly adhere to regulatory requirements and applicable standard operating procedures to promptly conduct investigation, evaluation, submission, follow-up investigations, and tracking of individual case reports. Concurrently, a professional drug safety monitoring team performs monitoring, verification, and assessment of product safety, and the Pharmacovigilance Advisory Committee performs related analysis. In addition, we take timely response measures to ensure effective monitoring and control of product safety.

Pharmacovigilance Training

In 2025, Akeso, Inc. enhanced the awareness and professional competence of all personnel regarding pharmacovigilance through a systematic, tiered training program.

To establish a comprehensive system for collecting and reporting safety-related information across the entire value chain, the Company conducts adverse event reporting training for all employees and provides dedicated training to newly hired personnel, ensuring that individuals at every stage — from research and development to commercialization — possess clear awareness and capability in reporting safety incidents.

In addition, a total of approximately 40 drug safety surveillance-related training sessions were conducted throughout the year, covering regulatory requirements, standard operating procedures, and hands-on practical training for key drug safety surveillance activities. These trainings effectively reached personnel across functions including drug safety surveillance, clinical development, clinical operations, and commercial operations. In addition, we have repeatedly organized pharmacovigilance personnel to participate in specialized training sessions on pharmacovigilance conducted by national and provincial regulatory authorities. The training covered key areas such as the pharmacovigilance quality system, lifecycle management, and adverse drug reaction monitoring, further enhancing the professional capabilities of the pharmacovigilance team.

5.3 SUPPLY CHAIN MANAGEMENT

Akeso, Inc., grounded in a systematic and standardized supplier management framework, has advanced the construction of a transparent supply chain and sustainable procurement practices. Through the establishment of a rigorous access evaluation mechanism and comprehensive lifecycle performance management, we continuously optimize the supply chain ecosystem, striving for the coordinated development of business ethics, environmental responsibility, and operational efficiency, thereby providing a robust foundation for the long-term stable operations of the enterprise and the high-quality advancement of the industry.

5.3.1 Supplier Management System

Akeso, Inc. has established and implemented multiple internal procedures, including the *Supplier Management Procedures for Production Materials* (《物料供應商管理程序》), the *Change Control Procedures* (《變更控制程序》), the *Procurement Management Procedures for Fixed Assets* (《固定資產採購管理程序》), and the *Procurement Management Procedures for Entrusting Services* (《委託服務採購管理程序》), to comprehensively manage all stages of supplier admission, evaluation, collaboration, and exit. To continuously enhance the standardization and transparency of supply chain management, the Company introduced and implemented six internal management systems during the fiscal year, including the *Procurement and Logistics Department Bidding Project Management Procedure* (《物流採購部招標項目管理程序》) and the *Procurement and Logistics Department Records Management Procedure* (《物流採購部檔案管理程序》), thereby strengthening control over critical stages within the procurement process.

To ensure controllable supply chain quality and risk mitigation, Akeso, Inc. requires all suppliers that pass the qualification review to sign the *Quality Assurance Agreement* (《質量保證協議》) and categorizes them into Classes A, B, and C for differentiated control measures. The Company conducts audits of suppliers through various methods, including document review, system questionnaire surveys, experimental evaluations, and on-site audits. The on-site audit is conducted by an audit team composed of personnel who have undergone professional training and possess the requisite qualifications, with a focus on evaluating the supplier's production environment, material quality, quality control measures, and documentation compliance, resulting in an objective audit report. After the report is approved, the Company implements an exit mechanism for suppliers that fail to meet the requirements, based on the assessment results, and continuously optimizes the list of qualified suppliers to ensure the quality and stability of material supply. In 2025, we conducted a total of 41 on-site audits, with a pass rate of 97.56%.

5.3 SUPPLY CHAIN MANAGEMENT (Continued)

5.3.1 Supplier Management System (Continued)

Table 5: Supplier Classification and Management Measures

Supplier category	Definition	Management measures
Class A	Suppliers who supply the materials that will directly come into contact with our final products or the materials whose quality will directly affect the product quality for our production	• <i>System Check List</i> • <i>Quality Assurance Agreement</i> • Information audit • Quality assessment experiment (risk assessment would be initiated to determine whether to conduct the experiment) • On-site audit
Class B	Suppliers who supply the materials that will indirectly come into contact with our final products or the materials whose quality will directly affect the product quality for our production	• <i>System Check List</i> • <i>Quality Assurance Agreement</i> • Information audit • Quality assessment experiment (risk assessment would be initiated to determine whether to conduct the experiment) • On-site audit (risk assessment would be initiated to determine whether to conduct the audit)
Class C	Suppliers which supply the materials that will not come into contact with our final products or the materials whose quality will not affect the product quality for our production	• <i>Quality Assurance Agreement</i> • Information audit

Table 6: Distribution of Suppliers of Akeso, Inc. in 2025

Geographical location of suppliers	Unit	Quantity
China (including Hong Kong, Macau, and Taiwan)	Number	469
Outside China	Number	47

5.3 SUPPLY CHAIN MANAGEMENT (Continued)

5.3.2 Sustainable Procurement

To establish a sustainable and responsible supply chain framework, Akeso, Inc. continuously integrates environmental, social, and governance (ESG) risk management into the full lifecycle of supplier management. In the supplier admission process, suppliers that have obtained ESG-related certifications such as ISO 14001 Environmental Management System certification, ISO 9001 Quality Management System certification, and ISO 45001 Occupational Health and Safety Management System certification, or those possessing equivalent ESG-related certifications, are prioritized for collaboration. In evaluating and during the audit process, we focus on suppliers' actual performance in environmental protection, energy and resource utilization, pollution control, employee rights protection, occupational safety, and business ethics. Through a systematic and traceable approach, we aim to continuously enhance suppliers' responsibility performance and jointly achieve sustainable development of the industrial chain. Furthermore, the Company requires that GMP material suppliers sign the *Quality Assurance Agreement* (《質量保證協議》), and all relevant purchase orders and contracts include anti-commercial bribery clauses to clearly define both parties' obligations regarding quality compliance, ethical business conduct, and integrity in cooperation, thereby establishing a robust institutional foundation for sustainable collaboration.

In 2025, to systematically manage supply chain ESG risks and advance sustainable development across the entire value chain, the Company further strengthened its supplier environmental and social performance review mechanism, conducting targeted reviews of 80 key material and service suppliers. The reviews were conducted through a combination of document evaluation and on-site verification, comprehensively examining its environmental and social performance. For suppliers failing to meet requirements, the Company initiated systematic closed-loop management of rectifications to ensure the development and implementation of corrective and preventive measures. This action has effectively driven continuous improvement among suppliers, providing strong support for the establishment of a robust, transparent, and responsible sustainable supply chain.

In addition, the Company adheres to the *Supplier Management Procedures for Production Materials* (《物料供應商管理程序》) and establishes a qualified backup supplier pool for all critical materials through multi-dimensional evaluation, thereby enhancing supply chain resilience and ensuring business continuity. We have developed alternative supply solutions for primary production materials through a comprehensive evaluation process encompassing market research, performance testing, and production validation, thereby effectively enhancing the supply chain's emergency response capability and resilience. During the Reporting Period, the Company completed the implementation of reliable alternative sourcing arrangements for materials such as packaging materials, auxiliary materials, and filters.

5.3.3 Supply Chain Integrity Construction

The Company continues to deepen supply chain integrity management based on the principles of "fairness, justice and openness". All procurement personnel are organized to sign the *Anti-commercial Bribery Undertaking Statement* (《反商業賄賂承諾書》), explicitly prohibiting the pursuit of improper benefits in business transactions. In addition, the Company has incorporated specific integrity clauses into all equipment procurement and service cooperation agreements, jointly building a trustworthy and transparent business ecosystem with its partners to mitigate integrity risks and ensure the practical implementation of transparent procurement and compliant collaboration.

6 PEOPLE-CENTRIC: STRENGTHENING CORE COHESION

Akeso, Inc. adheres to a talent-driven strategy, and continuously fosters a safe, equitable, dynamic, and growth-oriented work environment featuring a comprehensive employee rights protection system, structured career development and training programs, and rigorous occupational health and safety management. We are committed to enhancing employees' sense of belonging and well-being, and unlocking the organization's intrinsic potential, thereby establishing a solid talent foundation for sustainable, high-quality development.

6.1 PROTECTION OF EMPLOYEE RIGHTS

Akeso, Inc. adheres to equitable and transparent employment principles, safeguards employees' lawful rights and interests in accordance with regulations, and strives to build a cohesive and caring talent development platform through systematic compensation incentives and communication mechanisms.

6.1.1 Labor Rights and Interests

In strict accordance with the *Labor Law of the People's Republic of China* (《中華人民共和國勞動法》), the *Labor Contract Law of the People's Republic of China* (《中華人民共和國勞動合同法》), the *Employment Promotion Law of the People's Republic of China* (《中華人民共和國就業促進法》), the *Employment Ordinance of the Hong Kong Special Administrative Region* (Chapter 57 of the Laws of Hong Kong) and other applicable laws and regulations, Akeso, Inc. has formulated internal management policies such as the *Employee Handbook* (《員工手冊》), the *Administrative Measures for Overtime* (《加班管理辦法》), the *Management Procedures for Employee Attendance and Leave* (《員工考勤與休假管理規程》), the *Employee Onboarding and Offboarding Management System* (《員工入、離職管理制度》), the *Management Procedures for Dining, Accommodation, and Transportation* (《食宿行管理規程》), and the *Referral Bonus Management Measures* (《推薦工作獎管理辦法》), thereby safeguarding employees' rights and interests, and cultivating a high-performing, collaborative workforce.

We consistently adhere to the principles of "openness, fairness, competitiveness and meritocracy" in talent recruitment, and expand our talent pool through multiple channels, including campus recruitment, social recruitment, and introduction of internal and external talents. In addition, we take systematic measures to eliminate violations such as forced labor, employment of child labor, and employment discrimination, effectively safeguarding the legitimate rights and interests of employees. In the event of any violation of the employment principles, we promptly rectify relevant behaviors, provide appropriate compensation to affected employees, and seriously hold responsible personnel accountable in accordance with regulations.

As of the end of the Reporting Period, there were no incidents of child labor or forced labor at Akeso, Inc.

6.1 PROTECTION OF EMPLOYEE RIGHTS (Continued)

6.1.1 Labor Rights and Interests (Continued)

Table 7: Key Measures for Protection of Labor Rights and Interests

Anti-discrimination	Akeso, Inc. is committed to fostering a diverse, fair, open, and inclusive work environment, where we respect the individual backgrounds and dignity of every employee. We strictly adhere to the principle of equality and do not engage in any form of unfair treatment toward employees based on ethnicity, race, religious belief, gender, age, marital status, or sexual orientation.
Prevention of child labor	We strictly comply with the <i>Law of the People's Republic of China on the Protection of Minors</i> (《中華人民共和國未成年人保護法》), the <i>Provisions on the Prohibition of Using Child Labor</i> (《禁止使用童工規定》) and other applicable laws and regulations, and explicitly prohibit the employment of any person under the age of 18. During the formal recruitment process, the Human Resources Department is responsible for rigorously reviewing and verifying materials such as academic credentials, identity information, and medical examination reports of candidates, to ensure the authenticity and validity of the candidates' information and to eliminate the possibility of employing child labor or minors.
Opposition to forced labor	The Company firmly opposes any form of forced labor, slavery, and human trafficking. Moreover, the Company implements standard working hour system, consolidated working hour system, or irregular working hour system pursuant to laws to align with job characteristics and business needs, and reasonably arranges work and rest periods for employees.
Overtime compensation	We have formulated the <i>Administrative Measures for Overtime</i> (《加班管理辦法》) to clearly stipulate employees' entitlement to leave, overtime arrangements, and corresponding allowance standards, to appropriately compensate employees for their labor performed beyond statutory working hours and protect employees' legitimate rights and interests.

6.1 PROTECTION OF EMPLOYEE RIGHTS (Continued)

6.1.1 Labor Rights and Interests (Continued)

As of the end of the Reporting Period, Akeso, Inc. had 3,761 full-time employees. The classifications of our full-time employees by gender, age group, geographical location and employment type are set out in the charts below. During the Reporting Period, the overall employee turnover rate¹ was 23.30%. The classifications of employee turnover rate by gender, age group and geographic location are set out in the table below.

Table 8: Employee Turnover Rate of Akeso, Inc.

Types of employees		Unit	Turnover rate
Total employee turnover rate		%	23.30
Classified by gender	Male employees	%	26.31
	Female employees	%	21.06
Classified by age	Employees under the age of 30	%	21.73
	Employees aged 30 to 50	%	24.25
	Employees aged 51 or above	%	26.66
Classified by geographical location	Employees in China (including Hong Kong, Macau, and Taiwan)	%	23.29
	Employees outside China	%	25.00

¹ "Employee turnover" includes those formal employees with whom the employment relationships are terminated due to voluntary resignation, dismissal, retirement or death, excluding interns. Calculation method of employee turnover rate: Number of employee turnover in the current year/total number of such type of employees.

6.1 PROTECTION OF EMPLOYEE RIGHTS (Continued)

6.1.1 Labor Rights and Interests (Continued)




Fig: Total number of employees of Akeso, Inc. in 2025 classified by gender




Fig: Total number of employees of Akeso, Inc. in 2025 classified by age

6.1 PROTECTION OF EMPLOYEE RIGHTS (Continued)

6.1.1 Labor Rights and Interests (Continued)




Fig: Total number of employees of Akeso, Inc. in 2025 classified by geographical location




Fig: Total number of employees of Akeso, Inc. in 2025 classified by employment type

6.1 PROTECTION OF EMPLOYEE RIGHTS (Continued)

6.1.2 Communication with Employees

Akeso, Inc. consistently places significant emphasis on establishing transparent and efficient internal communication mechanisms. We have established dedicated communication processes for key stages, including onboarding, probation, and performance evaluations, to assist employees in clearly understanding company policies and job requirements, thereby facilitating their professional growth and development. Since the establishment of the labor union in 2014, the Company has constantly enhanced the employee feedback mechanism, under which we actively listen to and respect employees' demands, promptly respond to and implement reasonable suggestions, and genuinely focus on and assist in solving various difficulties in the work and the life of employees.

We have established formal and confidential grievance procedures to effectively address employee complaints and feedback. Diversified reporting and complaint channels, including dedicated email and Human Resources Department hotlines, are available. The Company implements standardized procedures for the investigation, handling, and follow-up of all complaints and reports, ensuring that each case is addressed in a fair and objective manner. The investigation results will be communicated to the complainants or whistleblowers in writing or by phone, and all personal information of the reporters, including name, position, address, and report details, will be strictly kept confidential to safeguard employees' rights, interests, and privacy.

6.1.3 Remuneration and Benefits

Akeso, Inc. adheres to the principles of "strategic orientation, justice and equity, performance-based remuneration, clarity and transparency, and benefit sharing". In addition to establishing a compensation management system with clear structure and scientific incentives in accordance with relevant laws and regulations, the Company has formulated internal management policies such as the *Administrative Measures for Remunerations* (《薪酬管理辦法》) and the *Performance Assessment Management Plan* (《績效考核管理方案》), which explicitly define the compensation structure consisting of basic salary, performance pay, comprehensive allowances, and variable year-end bonuses. This structure is designed to achieve reasonable alignment between value contribution and compensation return. In terms of performance management, the Company sets annual targets for departments and posts in a scientific manner, guided by its business strategies and annual goals. We conduct full-cycle, multi-dimensional performance evaluations, including probationary period assessments, monthly/quarterly evaluations for specific positions, and annual performance evaluations for all employees. By directing linking the completion of relevant targets to performance evaluations, the Company effectively motivates employee engagement and organizational vitality.

6.1 PROTECTION OF EMPLOYEE RIGHTS (Continued)

6.1.3 Remuneration and Benefits (Continued)

Strictly abiding by laws and regulations such as the *Social Insurance Law of the People's Republic of China* (《中華人民共和國社會保險法》), the Company legally contributes to social insurance and housing provident funds, and provides group commercial insurance and other statutory benefits for all employees. We implement leave management by fully offering statutory leaves, including paid annual leaves, sick leaves, and maternity leaves. In addition, we systematically design the non-mandated welfare system in the *Welfare Handbook* (《福利手冊》), which includes working meals, medical examination, transportation allowances, festival greetings, wedding and childbirth gifts, etc. In addition, we regularly organize birthday celebrations, family days, cultural and recreational activities, and team-building events, and have established an employee mutual fund to continuously foster an organizational atmosphere characterized by warmth and cohesion. To support employees' housing and professional development, we actively assist in the application for government-subsidized housing for talents, public rental housing, and various talent allowances. Additionally, we have established a postdoctoral workstation, offering competitive entry benefits, internal referral incentives, and special activity rewards to high-level talents, thereby systematically building an attractive talent development ecosystem.

6.2 DEVELOPMENT AND TRAINING

Akeso, Inc. continuously enhances the employee development and training system in close alignment with the Company's business strategies and development objectives, and provides clear career paths for employees, to offer fair and transparent promotion opportunities to all employees.

We are committed to building a highly skilled and professional workforce, and design systematic and differentiated training programs for employees at various positions and levels through annual training plans. The training programs encompass multiple dimensions, including onboarding training, specialized position training, professional skills training, and other relevant programs. Moreover, we actively encourage employees to participate in training programs in the forms of classroom-based courses and self-directed study. The Company supports employees in participating in accreditation of general skills and professional qualifications, to promote the diversified development of individuals' capabilities. In 2025, the Company offered training programs that collectively covered 3,760 employees, representing 100% of the headcount. This effectively enhances the overall professional competence and organizational vitality.

Details of the three training stages for new staff are as follows:

- Corporate-level training: Introduction of basic knowledge, including corporate overview, labor law and disciplines, and the Good Manufacturing Practice (GMP) of Medical Products;
- Department-level training: Training in safe production, laboratory management mechanism and occupational health and safety, as well as relevant departmental policies; and
- Position-level training: Training in equipment operation, equipment management and safe production.

6.2 DEVELOPMENT AND TRAINING (Continued)**Table 9: Training Overview of Akeso, Inc. in 2025**

Types of employees		Number of employees participating in training	Average training hour(s)	Percentage of employees trained
All employees		3,761	8	100%
By gender	Male employees	1,601	8	100%
	Female employees	2,160	8	100%
By position	Senior management	12	8	100%
	Middle management	550	8	100%
	Non-management employees	3,199	8	100%

6.3 OCCUPATIONAL HEALTH AND SAFETY

Akeso, Inc. has established a comprehensive safety, occupational health, and chemical management system covering all personnel, processes, and lifecycles, consistently fostering a safe and healthy working environment for employees and laying a solid foundation for the company's high-quality development.

6.3.1 Work Safety

Akeso, Inc. consistently complies with relevant laws and regulations, including the *Work Safety Law of the People's Republic of China* (《中華人民共和國安全生產法》), the *Fire Protection Law of the People's Republic of China* (《中華人民共和國消防法》), and the *Provisions on the Management and Supervision of the Fulfillment of Responsibility of Security Principals for Safety by Special Equipment Users* (《特種設備使用單位落實使用安全主體責任監督管理規定》). Based on these legal requirements, the Company has established and continuously refined a complete set of internal safety management standards including the *Safe Production Liability System* (《安全生產責任制》), the *Classified Control System for Safety Risks* (《安全風險分級管控制度》), the *Identification and Monitoring System for Sources of Major Dangers* (《重大危險源辨識和監控制度》), the *Contingency Proposal for Safety Production Incident* (《安全生產事故應急預案》), and the *Contingency Proposal for Barrier Environment of Laboratory* (《屏障環境實驗室應急預案管理制度》). These efforts contribute to a full-chain safety management framework encompassing hazard source prevention, process control, and result monitoring, thereby providing robust support for our sustained safe operations.

In daily safety management, the Company has established detailed safety operating specifications tailored to different positions and set up the Safety Production Committee. The committee sets specific targets for safety production control and accident prevention indicators annually, based on the size of personnel in each department, the condition of equipment, and the complexity of process flows. We require the personnel at all levels to sign the *Safe Production Declaration* (《安全生產責任書》), clearly defining the safety management responsibilities at all levels and implementing a graded accountability mechanism to effectively promote the achievement of safety production targets.

The Company places emphasis on the prevention and control of safety production risks by assigning both full-time and part-time safety management personnel to regularly organize safety inspections and potential safety risk troubleshooting, thereby effectively managing various safety and fire hazards. We define the responsibilities of the safety officers, safety directors, and relevant management personnel for special equipment to reinforce professional management, and organize systematic safety risk assessments made by designated personnel at each production position. In addition, we conduct special safety inspections on high-risk work areas, critical equipment, and key operational procedures on an irregular basis, and implement comprehensive safety assurance reviews prior to major holidays and festivals. All identified safety hazards must be immediately addressed by the respective responsible departments, teams, and projects.

The Company regularly reviews and updates internal emergency plans, enhancing employees' ability to respond to emergencies through simulated drills and specialized training for incidents such as fires and electric shocks. To continuously strengthen employees' safety awareness, we actively carry out a variety of safety education activities—including regular safety meetings, specialized training sessions, knowledge contests, and fire-fighting skill competitions, comprehensively enhancing employees' safety literacy and practical operational capabilities.

6.3 OCCUPATIONAL HEALTH AND SAFETY (Continued)

6.3.1 Work Safety (Continued)

In 2025, Akeso, Inc. achieved zero lost workdays due to work-related injury and did not experience any material safe production incidents.

Table 10: Number of Deaths Due to Work-Related Incidents at Akeso, Inc. in the Past Three Years

Performance indicators	Unit	2025	2024	2023
Number of deaths due to work	person	0	0	0

6.3.2 Occupational Health

In strict accordance with relevant laws and regulations such as the *Law of the People’s Republic of China on Prevention and Control of Occupational Diseases* (《中華人民共和國職業病防治法》), the *Provisions on the Supervision and Administration of Occupational Health at Workplaces* (《工作場所職業衛生監督管理規定》), and the *Measures for the Supervision and Administration of Employers’ Occupational Health Surveillance* (《用人單位職業健康監護監督管理辦法》), Akeso, Inc. has established and continuously refined the *Occupational Hazard Declaration System* (《職業病危害項目申報制度》), the *Management System for Occupational Hazard Monitoring and Evaluation* (《職業病危害監測及評價管理制度》), the *Emergency Rescue and Management System for Occupational Hazards* (《職業病危害應急救援與管理制度》), the *Responsibility System for Prevention and Treatment of Occupational Diseases* (《職業病防治工作責任制度》), the *Warning and Notification System for Hazards of Occupational Disease* (《職業病危害警示與告知制度》) and other internal management policies. Through a systematic approach, Akeso, Inc. has established an occupational health management system to effectively safeguard the occupational health and safety of all employees.

The Company ensures that all employees are provided with necessary emergency medical supplies, and the Human Resources Department systematically tracks and manages employees’ health status based on employee health archives. We provide professional personal protective equipment, including safety helmets, gas masks, and acid-alkali resistant gloves, as well as emergency decontamination facilities, to employees engaged in specific operations, and conduct ongoing supervision and guidance to ensure the standardized use of such protective equipment. In addition, we periodically engage qualified third-party agencies to detect and assess occupational hazards at the workplace, and organize targeted occupational health examinations for employees exposed to these hazards based on the evaluation results, to comprehensively safeguard employees’ health.

In strict accordance with the *Standard Operation Procedures of Health Management of Employees* (《工作人員健康管理標準操作規程》), we require personnel who are responsible for feeding laboratory animals and conducting animal experiments to receive holistic medical check-ups annually at designated medical institutions with appropriate qualifications, in order to promptly identify and control related occupational health risks.

6.3 OCCUPATIONAL HEALTH AND SAFETY (Continued)

6.3.3 Chemical Management

Akeso, Inc. regards chemical safety as a critical component of safe operations. In strict accordance with relevant national laws, regulations, and standards, the Company has established and continuously improved internal management systems, including the *Hazardous Chemical Safety Management System* (《危險化學品安全管理制度》), the *General Rules on Warehousing of Hazardous Chemicals* (《危險化學品倉庫儲存通則》), and the *Management Measures for Precursor and Explosive Chemicals* (《易制毒、易制爆化學品管理辦法》). We closely monitor regulatory developments, regularly update the list of chemicals under control, stipulate limited purchase and prohibited storage of precursor and explosive chemicals, and implement a requirement-based withdrawal and usage registration system.

The Company has established a unified chemical management record-keeping system, and provided complete monitoring facilities in the warehouse area to systematically oversee the entire process of chemicals — covering procurement, storage, classification, usage, warehousing, and disposal. We engage third-party agencies with corresponding qualifications for compliant disposal of all chemical waste, and provide necessary emergency supplies on site. Besides, we undergo regular inspections by the competent authorities to effectively prevent safety accidents such as leakage and intoxication.

In the chemical storage and use areas, we post prominent material Safety Data Sheets (SDS), safety warning signs, and related management systems to continuously strengthen onsite safety reminders. Additionally, we implement the requirements for chemical safety management systematically from the aspects of qualifications and operational specifications. Specifically, all employees involved in chemical operations should undergo specialized safety training and assessments, and officially handle chemicals upon passing the assessments and holding the Chemical Processing Certificate.

7 GREEN OPERATIONS: SHAPING A SUSTAINABLE FUTURE

Akeso, Inc. places environmental protection in a prominent position in its corporate sustainability strategy. The Company is committed to advancing green operations and ecological synergy by establishing a systematic environmental management system, continuously optimizing the emission management and resource utilization efficiency, actively developing and implementing adaptive strategies to address climate change.

7.1 ENVIRONMENTAL MANAGEMENT SYSTEM

Akeso, Inc. fully implements national environmental regulations, including the *Environmental Protection Law of the People's Republic of China* (《中華人民共和國環境保護法》) and the *Law of the People's Republic of China on Noise Pollution Prevention and Control* (《中華人民共和國噪聲污染防治法》), during its operations. In accordance with internal systems such as the *Environmental Management Ledger Record System* (《環境管理台賬制度》) and the *Administrative Measure for Waste Effluent, Gas Emission and Waste Residue Treatment* (《生產廢液、廢氣及廢渣處理管理制度》), the Company implements standardized management and compliant discharge of wastewater, exhaust gas, solid waste, and noise. The Company continuously reduces its potential environmental impact through the establishment of quantifiable environmental control goals, regular internal risk troubleshooting, and active cooperation with external regulatory evaluations. In addition, the Company adheres to the *Environmental Hazards Inspection System* (《環境隱患排查制度》), to systematically identify and assess potential environmental risk points within its operations, and implement routine inspection and fixed-point verification mechanisms for key facilities. Through the enhancement of preventive control measures, the Company has significantly strengthened the capability of proactively preventing and controlling environmental risks, thereby effectively reducing the likelihood of sudden environmental incidents.

To enhance the capability of responding to environmental emergencies, the Company has revised and implemented the *Emergency Response Plan for Environmental Emergencies* (《突發環境事件應急處置預案》), to systematically identify and evaluate environmental risk factors on a regular basis, and strictly regulate the full-process management of hazardous materials and waste in laboratories. With a sound emergency response organizational system in place, we equip corresponding rescue facilities, and regularly organize practical drills to continuously enhance environmental emergency preparedness and on-site response efficiency, thereby effectively preventing the risk of environmental pollution.

7.2 EMISSION MANAGEMENT

Akeso, Inc. continues to advance the systematic treatment and management of waste gas, wastewater, and waste, and establishes an environmental control system covering the entire production process to comprehensively reduce environmental impacts associated with operations and actively fulfill its responsibilities for green development.

7.2.1 Waste Gas Treatment

Akeso, Inc. strictly complies with relevant national and local environmental protection regulations and standards in exhaust gas management, including the *Atmospheric Pollution Prevention and Control Law of the People's Republic of China* (《中華人民共和國大氣污染防治法》), the *Regulation on the Administration of Permitting of Pollutant Discharges* (《排污許可管理條例》), and the *Emission Standard of Air Pollutants for Pharmaceutical Industry* (《製藥工業大氣污染物排放標準》) (GB 37823-2019). The Company systematically standardizes the full-process control over exhaust gas emissions to ensure compliance with environmental regulatory requirements.

To systematically control the emissions of sulfuric acid mist, hydrogen chloride, volatile organic compounds, non-methane hydrocarbons, and other waste gases generated during R&D and production, the Company has established a comprehensive management system covering waste gas generation, collection, and treatment. We install efficient exhaust gas collection and treatment facilities, and implement maintenance measures — including weekly routine inspections, airtightness testing of critical equipment, and timely replacement of adsorbents — to continuously enhance the efficiency of exhaust gas collection and treatment, thereby effectively reducing unorganized emissions. In addition, the Company strengthens standardized operational training for laboratory and production personnel to ensure that waste gas control measures in each process are effectively implemented, thereby enhancing the overall control over exhaust gas emissions.

Table 11: Air Pollutant Emissions of Akeso, Inc. in 2025

Air pollutant type	Unit	Emission
Sulfuric acid mist	kilogram	1.03
Hydrogen chloride ²	kilogram	8.26
Volatile organic compounds ³	kilogram	260.00
Non-methane hydrocarbons	kilogram	225.06

² In 2025, several products of Akeso, Inc. were included in the medical insurance catalog, leading to a significant increase in drug production, and the emission of hydrogen chloride increased in parallel with the expansion of production capacity.

³ In 2025, several products of Akeso, Inc. were included in the medical insurance catalog, leading to a significant increase in drug production, and the emission of volatile organic compounds increased in parallel with the expansion of production capacity.

7.2 EMISSION MANAGEMENT (Continued)

7.2.2 Wastewater Management

Akeso, Inc. strictly complies with relevant regulations, including the *Water Pollution Prevention and Control Law of the People's Republic of China* (《中華人民共和國水污染防治法》) and the *Regulation on the Administration of Permitting of Pollutant Discharges* (《排污許可管理條例》), and implements classified treatment and compliant discharge of various types of wastewater to ensure that water quality indicators consistently meet national standards. Wastewater generated by the Company during its manufacturing and operation primarily includes production sewage, cleaning sewage, and domestic sewage. The Company enhances monitoring of water collection facilities by additionally installing automatic monitoring equipment, and increases the frequency of routine inspections of drainage pipelines and collection facilities, thereby improving water utilization efficiency and environmental protection management level.

In 2025, the Company proactively advanced water-saving technological upgrades and resource recycling by recovering concentrated brine discharged from the pure water preparation system for park greening and landscape water supply. In addition, we recover steam condensate, and conduct thermal energy and water quality treatment, thereby achieving waste heat utilization and reuse of boiler feedwater. In addition, we continuously conduct water-saving awareness campaigns among all employees, encourage the preferential use of qualified cleaning sewage in production and operations, and constantly explore the ways of wastewater reuse to systematically advance sustainable water resource management. During the Reporting Period, Akeso, Inc. discharged a total of 71,709.08 tonnes of industrial wastewater.

Table 12: Sources of Wastewater and Treatment Methods

Wastewater types	Sources	Treatment methods
Production sewage	Culture solution in the production workshop, sewage generated from cleaning equipment and floor, etc.	Discharged into our sewage collection tank after being sterilized with high-pressure steam and transferred by a qualified third-party sewage treatment company for treatment on a regular basis
Domestic sewage	Sewage generated by employees in their daily activities	Discharged into municipal sewage pipe network and handed over to the urban sewage treatment plant for unified treatment after being treated by septic tanks in the plant
Clean sewage	Pure water preparation, industrial steam, etc.	Residuals collected are discharged into municipal sewage pipe network and handed over to the urban sewage treatment plant for unified treatment

7.2 EMISSION MANAGEMENT (Continued)

7.2.3 Waste Management

Akeso, Inc. conscientiously observes relevant regulations regarding solid waste management, including the *Law of the People's Republic of China on the Prevention and Control of Environmental Pollution Caused by Solid Wastes* (《中華人民共和國固體廢物污染環境防治法》), the *Regulation on the Administration of Permitting of Pollutant Discharges* (《排污許可管理條例》), and the *National Catalogue of Hazardous Wastes* (《國家危險廢物名錄》) (2025 Edition). In accordance with standards such as the *Technical Specification for Setting Identification Signs of Hazardous Waste* (《危險廢物識別標誌設置技術規範》) (HJ 1276-2022) and the amendment to the *Graphical Signs for Environmental Protection Solid Waste Storage (Disposal) Site* (《環境保護圖形標誌 — 固體廢物貯存(處置)場》) (GB 15562.2-1995), the Company has established an internal management system comprising the *Waste Management Practices* (《廢棄物管理規範》) and the *Administrative Measures for Prevention and Control of Environmental Pollution of Hazardous Wastes* (《危險廢棄物污染環境防治管理制度》). The Company has established standardized procedures for the classification, storage, transfer, and disposal of hazardous and non-hazardous waste during production and operations. Concurrently, the Company promotes reduction of waste from the source by requiring each responsible department to develop and implement the waste reduction plan, thereby fully embodying the principle of green operations.

For management of hazardous waste, the Company's EHS Department formulates annual *Management Plan for Hazardous Wastes* (《危險廢物管理計劃》), systematically reviewing the waste generated from operational processes such as production, procurement, and warehousing, and developing actionable waste reduction plan. The plan is reported and registered on the "Guangdong Solid Waste Environmental Supervision Information Platform" (廣東省固體廢物環境監管信息平台) as required, and has obtained approval from the ecological environment department. In addition, through enhanced cross-departmental collaboration, optimized production planning, and improved material control, we effectively reduce the generation of obsolete and expired materials, steadily advancing the achievement of the hazardous waste reduction target.

Table 13: Types of Waste and Treatment Methods

Types	Treatment methods	
Hazardous wastes	Hazardous waste (medical waste, pharmaceutical waste, laboratory waste effluent, and other hazardous wastes)	Transferred and treated by qualified third-party hazardous waste disposal agencies
Non-hazardous wastes	Recyclable waste (packaging boxes, wooden products, scrap metal, and scrap plastics)	Collected by recycling companies
	Non-recyclable waste (office and domestic wastes, and sludge)	Collected by sanitation companies, and sludge is treated by qualified third-party waste disposal agencies

7.2 EMISSION MANAGEMENT (Continued)

7.2.3 Waste Management (Continued)

Table 14: Waste Produced by Akeso, Inc. in 2025

Performance indicators	Unit	Amount produced
Hazardous waste production	tonne	332.24
Non-hazardous waste production	tonne	429.37
Average hazardous waste production per person	tonne/person	0.09
Average non-hazardous waste production per person	tonne/person	0.11

7.3 RESOURCE USAGE MANAGEMENT

Akeso, Inc. continues to strengthen the systematic management of energy, water resources, and packaging materials, with commitment to establishing a green and efficient resource utilization system. Through process optimization, implementation of recycling and energy-saving technologies, we effectively enhance the resource utilization efficiency, supporting the enterprise's low-carbon and sustainable development.

7.3.1 Energy Management

Akeso, Inc. regards energy management as a pivotal foundation of its climate response strategy. The Company is committed to optimizing its energy structure, expanding the application of clean energy, and advancing the green and low-carbon transformation of its production and operation segments. The Company strictly complies with relevant laws and regulations, including the *Energy Conservation Law of the People's Republic of China* (《中華人民共和國節約能源法》), and has established internal policies such as the *Management System for Office Energy Consumption* (《辦公能耗管理制度》) to further standardize employees' use of energy-consuming equipment in office areas, laboratories, and other premises, thereby effectively reducing energy waste in daily operations. During the Reporting Period, the main energy sources of Akeso, Inc. were electricity and purchased heat used for daily operations.

The Company has established clear energy management performance targets based on actual operating conditions, and dynamically monitors progress toward these targets through systematic recordkeeping and continuous analysis of energy consumption data. To further enhance energy utilization efficiency, the Company implements a series of targeted improvement measures.

7.3 RESOURCE USAGE MANAGEMENT (Continued)

7.3.1 Energy Management (Continued)

Table 15: Akeso, Inc.'s Energy Conservation Measures in 2025

Daily operations	- Replaced office lighting with LED fixtures - Procured internationally advanced equipment and facilities - Promoted video conferencing to reduce employee travel - Established a security patrol mechanism to oversee energy conservation efforts - After recovering the steam condensate, recovered part of the thermal energy through plate heat exchangers, and treated the water quality before being reused as boiler feedwater, thereby achieving energy savings through residual heat recovery and reducing the consumption of tap water
Logistics and transportation	- Implemented intelligent circular distribution systems - Utilized GPS technology to optimize transportation routes - Adopted new energy and fuel-efficient vehicles

Table 16: Energy Consumption of Akeso, Inc. in 2025

Performance indicators	Unit	Consumption
Energy consumption in total	kWh in '000s	120,750.27
Density of energy consumption	kWh in '000s/person	32.11
Gasoline consumption	liter	29,382.00
Diesel consumption ⁴	liter	30,180.20
Steam consumption	tonne	40,886.69
Purchased electricity consumption	kWh	61,856,830.81
Natural gas consumption	m ³	2,995,725.00
Average gasoline consumption per person	liter/person	7.81
Average diesel consumption per person	liter/person	8.03
Average steam consumption per person	tonne/person	10.87
Average purchased electricity consumption per person	kWh/person	16,451.28
Average natural gas consumption per person	m ³ /person	796.74

⁴ In 2025, extreme weather events occurred more frequently than in 2024, and the Company activated diesel generators to supply power in response to municipal power supply anomalies.

7.3 RESOURCE USAGE MANAGEMENT (Continued)

7.3.2 Water Resource Management

Water resources have a critical impact on human life and corporate operations. Recognizing the importance of water resources, Akeso, Inc. strictly complies with relevant laws and regulations, including the *Administrative Regulations on Urban Water Conservation* (《城市節約用水管理規定》), sets water resource management goals, and continuously enhances water use efficiency in proactive response to the challenges associated with sustainable water resource development. The Company has established a routine monitoring mechanism for water resources, integrating regular inspections with random inspections to enable real-time surveillance and early warning of abnormal water usage in canteens, office areas, and washrooms. We also install water storage tanks, and designate personnel to maintain water-related facilities such as pure water machines and faucets every day, to promptly identify and address abnormal water consumption. For enhancing the water utilization efficiency, the Company actively promotes the compliant reuse of clean sewage in scenarios such as landscape irrigation, and continues to explore additional pathways for wastewater recycling. For high-volume water equipment such as pure water machines and cooling water towers, we install dedicated water meters to enable precise monitoring and statistical analysis of water usage. Additionally, we promote the use of water purification devices in office areas to gradually replace barreled water, thereby reducing operational costs and minimizing water consumption.

In addition, the Company conducts regular specialized training sessions on water resource management and continuously strengthens all employees' awareness of water conservation through daily promotion initiatives, systematically enhancing overall water-saving capabilities and green operational performance.

During the Reporting Period, water resources used by Akeso, Inc. were from the municipal pipe network, and there was no difficulty in the supply and purchase of water resources.

Table 17: Water Resource Consumption of Akeso, Inc. in 2025

Performance indicators	Unit	Consumption
Municipal water consumption	tonne	885,485.00
Average municipal water consumption per person	tonne/person	235.50

7.3 RESOURCE USAGE MANAGEMENT (Continued)

7.3.3 Packaging Material Management

Akeso, Inc. has established a sustainable management model characterized by “lightweight design — eco-friendly procurement — circular reuse”, aiming to achieve the integration of environmental friendliness and resource efficiency in the packaging process. During the packaging development stage, the Company facilitates the design of simplified and lightweight packaging materials, and continuously optimizes the structure for material savings while maintaining product protection performance. In the procurement and supply process, we prioritize recyclable and renewable environmentally friendly materials, to actively promote the recycling of packaging materials. During the Reporting Period, Akeso, Inc. primarily utilized paper-based outer packaging materials for finished products.

Table 18: Consumption of Packaging Materials of Akeso, Inc. in 2025

Performance indicators	Unit	Consumption
Consumption of paper packaging materials ⁵	kilogram	103,060.00
Consumption of paper packaging materials per person	kilogram/person	27.41

7.4 RESPONSE TO CLIMATE CHANGE

Climate change has emerged as a serious global challenge. Akeso, Inc. has long been committed to advancing green development within the industry. In active response to the national “dual carbon” (carbon peaking and carbon neutrality) strategy, the Company has established a carbon neutrality strategy and set related targets. The Company continues to explore effective approaches to address climate change and comprehensively drives low-carbon development across the industrial chain, contributing enterprise-level efforts toward global green and low-carbon development.

7.4.1 Governance

Akeso, Inc. adheres to the principle of green development and incorporates climate-related factors into its strategic decision-making and daily operational management in accordance with the framework and recommendations issued by the Task Force on Climate-related Financial Disclosures (TCFD), aiming to create long-term and stable environmental value.

The Company has established a comprehensive climate change governance framework, continuously strengthening the foundation of governance, enhancing management efforts, and improving effectiveness at the execution level. We have established a three-tier ESG governance structure comprising the Board of Directors, the ESG Working Group, and key executive departments, and incorporate climate-related risks into the Company’s overall risk management framework, enabling systematic identification, assessment, and response decision-making regarding climate-related risks. In addition, we designate “Response to climate change” as one of the Company’s core ESG issues. The ESG Working Group, in accordance with the Board’s strategic deployment, develops an annual ESG action plan encompassing climate-related topics, continuously identifies and manages climate-related risks, promotes the effective implementation of relevant measures, and reports progress to the Board on a regular basis, thereby continuously enhancing the synergy between climate governance and business strategies.

⁵ In 2025, several products of Akeso, Inc. were included in the medical insurance catalog, leading to a significant increase in drug production, and the consumption of packaging materials increased in tandem with the expansion of production capacity.

7.4 RESPONSE TO CLIMATE CHANGE (Continued)

7.4.2 Strategy

Akeso, Inc. continuously monitors geographic and climatic information, and regularly conducts identification and analysis of climate-related risks in conjunction with dynamic changes in external regulatory policies, with the objective of further identifying the potential impacts of risks and opportunities, to develop comprehensive response measures to reduce adverse effects on business operations. Two physical risks and five transition risks, along with their respective response measures during the Reporting Period are as follows.

Table 19: Identification and Response of Climate Change Risks

Risk category	Risk type	Risk description	Response measures
Physical risks	Acute risks	Frequent extreme weather events, such as extreme heat, cold snaps, heavy rainfall, typhoons, and flooding, may lead to disruptions in the Company's production operations and logistics, while also posing safety risks to employees.	➤ We develop multiple specialized emergency response plans, including the <i>Contingency Plan for Safe Production Accidents</i> (《生產安全事故應急預案》), and the <i>Typhoon Emergency Command Plan</i> (《防颱風應急指揮預案》), establish a dedicated emergency team with clearly defined responsibilities of each member, and enhance the emergency command structure for extreme weather conditions. We also establish response measures for situations such as typhoons and heavy rainfall, store emergency supplies in advance, and systematically enhance the capability to respond to disasters, with the objective of minimizing potential personnel injuries and property losses caused by extreme weather. ➤ We implement a routine inspection mechanism in daily operation to systematically identify field equipment and facilities susceptible to extreme weather, and take timely measures to eliminate potential risks. In addition, we strengthen the inspection and protection of outdoor fixed fixtures, electrical instruments and equipment to prevent safety hazards such as falling objects from heights. ➤ With regard to warehouse management, we closely monitor the storage of raw materials, auxiliary materials, and finished products, and establish scientific and reasonable stocking strategies. In addition, we conduct regular inspections and maintenance of the drainage system, and equip emergency drainage equipment and flood prevention supplies in advance to enhance the response to the flood season.

7.4 RESPONSE TO CLIMATE CHANGE (Continued)

7.4.2 Strategy (Continued)

Risk category	Risk type	Risk description	Response measures
Physical risks (Continued)	Chronic risks	Chronic risks arising from climate change-such as rising sea levels, water scarcity, humid air, and average warming-may lead to various risks, such as increased costs in water and energy consumption, deteriorated quality of raw materials and products due to moisture, and reduced production efficiency due to rusting and aging of factory equipment.	➤ We set water resource management goals, with a focus on reducing fresh water consumption and improving the rate of wastewater recycling. ➤ We establish energy management performance indicators, and continuously improve energy use efficiency through energy-saving renovations and technological upgrades. ➤ In the area of logistics, we adopt an intelligent circular distribution model to optimize vehicle scheduling and resource allocation, thereby effectively reducing the empty load rate of transportation vehicles. ➤ We proactively promote the adoption of new energy-efficient vehicles and new energy transportation means to continuously reduce carbon emissions during operations.

7.4 RESPONSE TO CLIMATE CHANGE (Continued)

7.4.2 Strategy (Continued)

Risk category	Risk type	Risk description	Response measures
Transition risks	Regulatory risks	The international and domestic regulatory agencies and capital market rating indicators constantly increase their disclosure requirements for corporate environmental data. In the meanwhile, to cooperate with the implementation of carbon trading, the government has increased requirements for the accuracy of carbon emission data declared by enterprises. If the Company fails to disclose corresponding environmental information in accordance with relevant laws, regulations, and policies, it will be confronted with compliance risks.	➤ We continuously monitor and study the evolving policies related to green, low-carbon initiatives, proactively engage with regulatory authorities and stakeholders, and promptly interpret and respond to policy directions. ➤ We actively promote carbon reduction practices by encouraging the use of video conferencing and other alternatives to reduce business trips, and carry out regular awareness campaigns to advocate low-carbon work and travel. ➤ We communicate the importance of energy conservation, consumption reduction and resource conservation to employees, and continuously enhance the organization-wide awareness of energy conservation and emission reduction, to jointly facilitate green operations.

7.4 RESPONSE TO CLIMATE CHANGE (Continued)

7.4.2 Strategy (Continued)

Risk category	Risk type	Risk description	Response measures
Transition risks (Continued)	Litigation risks	Fines and judgments result in increased costs and/or reduced demands for products.	➤ We have established and continue to enhance the environmental management system, with a focus on preventing potential environmental risks, ensuring compliance with environmental regulations in its operations, and avoiding adverse impacts on the environment.
	Technical risks	Technological improvements or innovations that support the transition to a low-carbon and energy-efficient economic system may generate an impact on business operation.	➤ We steadily advance the energy conservation renovation of existing buildings, and reduce electricity consumption in offices through measures such as installing LED lighting equipment and using high-efficiency air conditioners. ➤ We phase out fossil fuel-based heating systems and enhance electrification to reduce carbon emissions, while exploring low-carbon energy alternatives such as solar heat, heat pumps, and biomass energy. ➤ We apply the GPS to enable full-process visual monitoring of vehicles, and optimize transportation route planning to shorten driving distance, thereby enhancing the overall efficiency of freight transportation.

7.4 RESPONSE TO CLIMATE CHANGE (Continued)

7.4.2 Strategy (Continued)

Risk category	Risk type	Risk description	Response measures
Transition risks (Continued)	Market risks	Changes in consumer behaviors, uncertainty in market signals, and increased raw material costs cause potential market risks.	➤ We advance the optimization of product packaging design to reduce the use of unwanted packaging materials at the source, and preferably select environmentally friendly, green materials. ➤ In active response to consumers' demands for low-carbon and environmentally friendly products, we take targeted measures to meet customer expectations, and fully consider sustainable preferences of clients in product development and service delivery.
	Reputational risks	Poor ESG performance or insufficient efforts to address climate-related issues may lead to negative feedback from consumers and other stakeholders, which may have an impact on product sales.	➤ We strictly comply with applicable regulations to ensure the legality and standardization of ESG information disclosure. ➤ We disclose climate-related risks and opportunities, along with corresponding management measures, in the ESG report, and continue to monitor the potential impacts of climate change in order to prevent risks that could adversely affect the organization's reputation. ➤ We take actions to address climate change and strategically promote our low-carbon image, with a focus on enhancing our green reputation and brand value associated with sustainable development.

7.4 RESPONSE TO CLIMATE CHANGE (Continued)

7.4.3 Risk Management

Akeso, Inc. has established complete climate risk management processes and integrated climate risk management into its enterprise risk management framework, to make timely and effective response to challenges posed by climate change. For more details, please refer to “4.3 Risk Management”. We evaluate and categorize the climate risk-related efforts, and develop a systematic risk prevention and control strategy centered on “prevention-adaptation-mitigation”. This includes measures such as disaster-resistant facility upgrades, organization of emergency drills and training programs to improve the climate risk response mechanism. On this basis, we refine the full-cycle closed-loop management encompassing risk identification, stress testing, and dynamic adjustment, thereby ensuring the effectiveness of climate-related efforts.

7.4.4 Metrics and Targets

To strengthen the foundational management capabilities for achieving targets and monitor the Company's carbon reduction performance, Akeso, Inc. conducts rigorous, regular tracking and monitoring of its direct and indirect greenhouse gas emissions and emission intensity. During the Reporting Period, the Company's greenhouse gas emissions mainly consisted of indirect emissions generated from electricity and purchased heat used for equipment and lighting systems in offices and projects under construction.

Table 20: Greenhouse Gas Emissions of Akeso, Inc. in 2025

Performance indicators	Unit	Emissions
Greenhouse gas emissions (Scope 1)	tCO ₂ e	6,622.89
Greenhouse gas emissions (Scope 2) (location-based method)	tCO ₂ e	44,935.62
Total greenhouse gas emissions (Scope 1 and Scope 2)	tCO ₂ e	51,558.50
Greenhouse gas emissions per person	tCO ₂ e/person	13.71

8 PUBLIC WELFARE: EMPOWERING THE SOCIETY

In response to the call of the *Opinions on Strengthening the Modernization of the Primary Governance System and Governance Capability* (《關於加強基層治理體系和治理能力現代化建設的意見》), Akeso, Inc. proactively fulfills its corporate social responsibility and deeply participates in charitable practices in public health and community development. Leveraging its professional expertise and resources, the Company has participated for consecutive years in the large-scale public welfare initiative “Zhongshan Charity Parade” focusing on the theme of “Red Cross Warmth Delivery”. Through targeted donations via Zhongshan Branch Red Cross Society of China, the Company supports key public welfare projects, including hospital construction, educational development, residential projects, and facilities for the elders. In addition, the Company continuously promotes and encourages employees to actively participate in volunteer services and give back to community, collectively contributing to the development of a harmonious and sustainable society.

Table 21: Charitable Donations of Akeso, Inc.

Performance indicators	Unit	Amount
Amount of charitable donations	RMB	100,000
Volunteer participation hours	hour	900

9 APPENDIX: CONTENT INDEX OF APPENDIX C2 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING CODE

This report is prepared in accordance with the Appendix C2 *Environmental, Social and Governance Reporting Code* of the Stock Exchange of Hong Kong Ltd. The table below sets forth the response index to the general disclosures and key performance indicators.

Subject Areas, Aspects, General Disclosures and KPIs			Section
A. Environmental			
Aspect A1: Emissions	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	7.2 EMISSION MANAGEMENT
	KPI A1.1	The types of emissions and respective emissions data.	7.2 EMISSION MANAGEMENT
	KPI A1.2	[Repealed 1 January 2025]	/
	KPI A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	7.2 EMISSION MANAGEMENT
	KPI A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	7.2 EMISSION MANAGEMENT
	KPI A1.5	Description of emission target(s) set and steps taken to achieve them.	7.2 EMISSION MANAGEMENT
	KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	7.2 EMISSION MANAGEMENT

9 APPENDIX: CONTENT INDEX OF APPENDIX C2 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING CODE (Continued)

Subject Areas, Aspects, General Disclosures and KPIs			Section
Aspect A2: Use of Resources	General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	7.3 RESOURCE USAGE MANAGEMENT
	KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	7.3 RESOURCE USAGE MANAGEMENT
	KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	7.3 RESOURCE USAGE MANAGEMENT
	KPI A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	7.3 RESOURCE USAGE MANAGEMENT
	KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	7.3 RESOURCE USAGE MANAGEMENT
	KPI A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	7.3 RESOURCE USAGE MANAGEMENT
Aspect A3: The Environment and Natural Resources	General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	7.1 ENVIRONMENTAL MANAGEMENT SYSTEM
	KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	7.1 ENVIRONMENTAL MANAGEMENT SYSTEM
Aspect A4: Climate Change	General Disclosure	[Repealed 1 January 2025]	/
	KPI A4.1	[Repealed 1 January 2025]	/

9 APPENDIX: CONTENT INDEX OF APPENDIX C2 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING CODE (Continued)

Subject Areas, Aspects, General Disclosures and KPIs			Section
B. Social			
Aspect B1: Employment	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	6.1 PROTECTION OF EMPLOYEE RIGHTS
	KPI B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	6.1 PROTECTION OF EMPLOYEE RIGHTS
	KPI B1.2	Employee turnover rate by gender, age group and geographical region.	6.1 PROTECTION OF EMPLOYEE RIGHTS
Aspect B2: Health and Safety	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	6.3 OCCUPATIONAL HEALTH AND SAFETY
	KPI B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	6.3 OCCUPATIONAL HEALTH AND SAFETY
	KPI B2.2	Lost days due to work injury.	6.3 OCCUPATIONAL HEALTH AND SAFETY
	KPI B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	6.3 OCCUPATIONAL HEALTH AND SAFETY
Aspect B3: Development and Training	General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	6.2 DEVELOPMENT AND TRAINING
	KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	6.2 DEVELOPMENT AND TRAINING
	KPI B3.2	The average training hours completed per employee by gender and employee category.	6.2 DEVELOPMENT AND TRAINING

9 APPENDIX: CONTENT INDEX OF APPENDIX C2 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING CODE (Continued)

Subject Areas, Aspects, General Disclosures and KPIs			Section
Aspect B4: Labor Standards	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	6.1 PROTECTION OF EMPLOYEE RIGHTS
	KPI B4.1	Description of measures to review employment practices to avoid child and forced labour.	6.1 PROTECTION OF EMPLOYEE RIGHTS
	KPI B4.2	Description of steps taken to eliminate such practices when discovered.	6.1 PROTECTION OF EMPLOYEE RIGHTS
Aspect B5: Supply Chain Management	General Disclosure	Policies on managing environmental and social risks of the supply chain.	5.3 SUPPLY CHAIN MANAGEMENT
	KPI B5.1	Number of suppliers by geographical region.	5.3 SUPPLY CHAIN MANAGEMENT
	KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	5.3 SUPPLY CHAIN MANAGEMENT
	KPI B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	5.3 SUPPLY CHAIN MANAGEMENT
	KPI B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	5.3 SUPPLY CHAIN MANAGEMENT

9 APPENDIX: CONTENT INDEX OF APPENDIX C2 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING CODE (Continued)

Subject Areas, Aspects, General Disclosures and KPIs			Section
Aspect B6: Product Responsibility	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	5.1 QUALITY MANAGEMENT
	KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	5.1 QUALITY MANAGEMENT
	KPI B6.2	Number of products and service related complaints received and how they are dealt with.	5.1 QUALITY MANAGEMENT
	KPI B6.3	Description of practices relating to observing and protecting intellectual property rights.	4.2 INTELLECTUAL PROPERTY PROTECTION
	KPI B6.4	Description of quality assurance process and recall procedures.	5.1 QUALITY MANAGEMENT
	KPI B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	During the Reporting Period, the Company did not collect any consumer data and privacy as all sale activities were conducted by our partners. This indicator is not applicable.

9 APPENDIX: CONTENT INDEX OF APPENDIX C2 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING CODE (Continued)

Subject Areas, Aspects, General Disclosures and KPIs			Section
Aspect B7: Anti-corruption	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	4.1 BUSINESS ETHICS
	KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	4.1 BUSINESS ETHICS
	KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	4.1 BUSINESS ETHICS
	KPI B7.3	Description of anti-corruption training provided to directors and staff.	4.1 BUSINESS ETHICS
Aspect B8: Community Investment	General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	8 PUBLIC WELFARE: EMPOWERING THE SOCIETY
	KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	8 PUBLIC WELFARE: EMPOWERING THE SOCIETY
	KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	8 PUBLIC WELFARE: EMPOWERING THE SOCIETY

